Thursday, October 10, 2024
HomeZzzz out of useAlzheimer's & DementiaCan dementia be prevented with stricter blood pressure control? 

Can dementia be prevented with stricter blood pressure control? 

A recent study investigated whether intensive blood pressure control could help prevent dementia in patients with high blood pressure.

Dementia is characterized by a loss of cognitive functioning that interferes with the ability to perform daily activities.

Alzheimer’s is the most common form of dementia. Mild cognitive impairment (MCI) is the clinical state between normal age-related cognitive decline and dementia.

In many observational studies, high blood pressure has been identified as a potential risk factor for MCI and dementia, as many Alzheimer patients have damage to their blood vessels.

No studies to date have been able to draw conclusive evidence regarding the effects of blood pressure control on dementia risk.

To address this gap in the literature, SPRINT Mind Investigators from the United States conducted the Systolic Blood Pressure Intervention Trial (SPRINT) to compare the effects of intensive blood pressure control versus standard blood pressure control on the risk of developing dementia. Their results were published in JAMA.

The trial included patients from over a hundred different sites in the United States and Puerto Rico who were older than 50 years of age with blood pressure between 130 and 180 mmHg and a high risk of cardiovascular disease.

The trial excluded patients with a diagnosis of dementia, diabetes, or a history of stroke.

The subjects were randomized to the intensive blood pressure control treatment group (systolic blood pressure target of less than 120 mmHg) or the standard blood pressure control group (systolic blood pressure target of less than 140 mmHg).

Cognitive assessments were done at baseline and during follow-up.

They first wanted to determine the incidence of probable dementia, and also looked at MCI occurrence and the combined occurrence of MCI or probable dementia.

The SPRINT trial was stopped early after 3.3 years because of the benefits seen with intensive blood pressure control management in cardiovascular disease and death.

However, the researchers continued to assess for dementia and MCI development for the full 5 years as originally planned.

Of the 9361 subjects enrolled in the study, 149 subjects in the intensive treatment group were identified as having probable dementia compared to 176 subjects in the standard group.

This finding was not statistically significant.

On the other hand, the occurrence of mild cognitive impairment was found to be significantly reduced in the intensive blood pressure control treatment group compared to the standard group.

Although mild cognitive impairment is considered a strong risk factor for the development of dementia, it was not a primary outcome of this trial and the long-term implications of this result on progression to dementia are still unknown.

Despite the study’s inability to find a significant reduction in dementia risk with a strict blood pressure control target of less than 120 mmHg, it is the first to explore the effects of a modifiable risk factor in dementia prevention.

Currently, there are no treatments to prevent or delay the progression of dementia, which is now the focus of current dementia research.

This study paves the way for future studies to investigate potential ways to prevent dementia or slow its progression.

Written by Maggie Leung, PharmD

Relevant topics that may be of interest to you:

References:

  1. Williamson, J. D., Pajewski, N. M., Auchus, A. P., Bryan, R. N., Chelune, G., Cheung, A. K., . . . Wright, C. B. (2019). Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia. Jama,321(6), 553. doi:10.1001/jama.2018.21442
  2. Balintfy, J. (2019, January 28). Does intensive blood pressure control reduce dementia? Retrieved from https://www.eurekalert.org/pub_releases/2019-01/nioa-dib012419.php
Maggie Leung PharmD
Maggie Leung PharmD
Maggie is a registered pharmacist and has a PharmD from the University of Toronto. She currently works in the pharmacy informatics field as a clinician applications consultant. In her role, she supports the integration and optimization of technology in healthcare. She enjoys learning about the latest in scientific research and sharing that knowledge through her writing for Medical News Bulletin. Maggie is a big dog lover and enjoys traveling and spending time with her friends and family.
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News and Articles

SUBSCRIBE TO OUR NEWSLETTERS

Stay Connected
10,288FansLike
820FollowersFollow
249FollowersFollow
2,787FollowersFollow

Article of the month

ANKTIVA Boosts BCG for Bladder Cancer

The FDA has approved the immunotherapy-boosting drug, ANKTIVA, to be used with the existing immunotherapy drug, Bacillus Calmette-Guerin (BCG). This new therapy is a...

Joke Of The Day

Patient: Doctor, I think there are two of me. Psychiatrist: Well, why don’t you both sit down and one of you tell me all about it.

ADVERTISE WITH US

error: Content is read-only and copy-protected.